Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer

Abstract

Matrix metalloproteinases (MMPs) are frequently expressed in malignant tumors and play an important role in tumor invasion and metastasis. The aim of this study was to evaluate role of serum MMP-2 and MMP-7 levels in patients with ovarian cancer. Serum levels of MMP-2 and MMP-7 were measured in 28 patients with ovarian carcinoma, 2 with borderline ovarian tumors, 10 with non-malignant gynecological disease and 30 healthy women by Enzyme-Linked Immunosorbent Assay (ELISA). Serum MMP-7 level was significantly (10.24+/-1.35 ng/ml) higher in the patients with ovarian malign tumors than healthy controls (3.29+/-1.64 ng/ml) (P<0.05). Postoperative levels of MMP-7 (7.68+/-1.17 ng/ml) were significantly lower in patients with malign ovarian tumors than those of preoperative level (10.24+/-1.35 ng/ml) (P<0.05). Serum MMP-2 levels were significantly lower in the patients with ovarian malign tumors (227.51+/-9.91 ng/ml) than those in the healthy controls (279.12+/-73 ng/ml) (P<0.05). There was no significant difference in serum levels of MMP-2 and MMP-7 in patients with benign ovarian disease when compared to healthy controls and patients with malignant disease (P>0.05). As a conclusion, MMP-7 can be a useful serum marker to show disease activity in malignant ovarian tumors.

Genetic polymorphisms in MMP7 and reduced serum levels associate with the development of bronchiolitis obliterans syndrome after lung transplantation

“…21,32 We found that serum levels of MMP7 were increased in the allograft recipients and that this increase was genotype-and haplotype-dependent. These data indicate that MMP7 genotype has an effect on protein levels but only under conditions of cellular stress, such as after lung transplantation, and not during steady-state conditions, such as in healthy individuals.…”

“…[12][13][14] MMP-7 thus far has not been studied in the context of BOS, although its function has been established in fibrotic lung diseases such as idiopathic pulmonary fibrosis and, in particular, the development of various cancers. [15][16][17][18][19][20][21] MMP-7 has a broad substrate specificity, being able to degrade elastin, proteoglycans, type IV collagen, and other components found in the lung matrix. 9,22 It is a protein constitutively produced by the epithelium of several noninjured, non-inflamed tissues, such as lung, liver, and breast.…”

Matrix metalloproteinases in the pathophysiology and progression of gynecological malignancies: could their inhibition be an effective therapeutic approach?

“…However, they did note that activated MMP-2 levels were related to disease invasiveness, metastasis and progression. Increased serum MMP-7 levels have also been found in patients with malignant ovarian tumors, using ELISA [82], while high-levels of MMP-14 expression have been recently reported to contribute to both the proliferative capacity and the enhanced parenchymal metastasis of ovarian clear cell carcinoma [83]. Studies investigating the role of MMPs in polycystic ovary syndrome (PCOS), have noted that women with PCOS have significantly higher serum concentrations of MMP-2, -9 and TIMP-1 but not TIMP-2 [84,85].…”

“…Rauvala et al [129] concluded that the sequential measurement of serum MMP-2, MMP-9 and TIMP-2 during chemotherapy of optimally operated patients might be useful for treatment response evaluation. More importantly, Acar et al [82] concluded that serum MMP-7 could be a useful marker of disease activity in malignant ovarian tumors, since its preoperative levels were significantly (p < 0.05) lower compared with postoperative ones (10.24 ± 1.35 ng/ml and 7.68 ± 1.17 ng/ml respectively).…”

The Contribution of MMP-7 Promoter Polymorphisms in Renal Cell Carcinoma

“…In 2016, Niedworok and his colleagues' findings also showed elevated serum levels in metastatic compared to non-metastatic RCC cases (19). Thus, MMP-7, in addition to carbonic anhydrase IX, VEGF, IL-6 and CRP, may serve as a promising serum marker for the detection of metastasis and prediction of poor survival for RCC, similarly to other cancers including gastric (22), colorectal (23,24) and ovarian cancer (25). There are several limitations in this study.…”